Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program
23 juin 2014 mis à jour par: St. Jude Children's Research Hospital
Sickle cell disease (SCD) is a debilitating genetic disorder affecting 70,000-100,000 Americans. It is frequently associated with very serious medical complications. For children with SCD, successfully transitioning to adult care is a vital step in ensuring continuity of care, managing their disease, and improving their health outcomes. Transition programs have been created to facilitate the transition process. However, few studies have assessed transition readiness and whether transition program components meet the transition needs of patients and families.
The purpose of this study is to explore transitioning from pediatric care to adult care and to assess components of the SJCRH SCD Transition Program from three perspectives: adolescents with SCD, their caregivers, and young adults with SCD who have transitioned to adult care. Data collection methods will include focus groups, questionnaires, and checklists. Qualitative data analysis procedures will be used to examine the data.
Aperçu de l'étude
Description détaillée
In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program.
Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program.
Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Type d'étude
Observationnel
Inscription (Réel)
55
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Tennessee
-
Memphis, Tennessee, États-Unis, 38105
- St. Jude Children's Research Hospital
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
12 ans à 30 ans (Enfant, Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
Méthode d'échantillonnage
Échantillon non probabiliste
Population étudiée
- Adolescents with SCD (all genotypes) ages ≥ 12 years old and ≤ 18 years old and currently receiving services through the SJCRH Sickle Cell Disease Transition Program
- Caregiver of an adolescent with SCD who has resided with the adolescent for at least 2 years prior
- Young adults with SCD (all genotypes) ages ≥ 18 years old and ≤ 30 years old who have transitioned to adult care
La description
Inclusion Criteria:
- Adolescents with SCD (all genotypes) ages ≥ 12 years old and ≤ 18 years old and currently receiving services through the SJCRH Sickle Cell Disease Transition Program.
- Caregivers who have resided with the adolescent with SCD for at least 2 years prior.
- Young adults with SCD (all genotypes) ages ≥ 18 years old and ≤ 30 years old who have transitioned to adult care
Exclusion Criteria:
- Non-English speakers.
- Adolescents and young adults with sickle cell trait.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Adolescents
Adolescents with SCD (all genotypes) age 12 years old up to 18 years old and currently receiving services through the St. Jude Children's Research Hospital Sickle Cell Disease Transition Program.
|
In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program.
Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program.
Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Autres noms:
|
|
Caregivers
Caregiver of an adolescent with SCD who has resided with the adolescent for at least two years prior.
|
In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program.
Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program.
Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Autres noms:
|
|
Young Adults
Young adults with SCD (all genotypes) age equal to 18 years up to and equal to 30 years of age who have transitioned to adult care.
|
In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program.
Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program.
Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Grounded theory qualitative analysis of data
Délai: 1 day
|
First, data will be prepared for qualitative analysis.
Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel data file.
Second, focus group data will be qualitatively analyzed using the constant comparative process.
A qualitative data analysis program, NVivo9 (Victoria, Australia) will be used to assist with this coding process.
|
1 day
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 mars 2012
Achèvement primaire (Réel)
1 mars 2014
Achèvement de l'étude (Réel)
1 mars 2014
Dates d'inscription aux études
Première soumission
30 mars 2012
Première soumission répondant aux critères de contrôle qualité
2 avril 2012
Première publication (Estimation)
3 avril 2012
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
24 juin 2014
Dernière mise à jour soumise répondant aux critères de contrôle qualité
23 juin 2014
Dernière vérification
1 juin 2014
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- XPD12-025 TRANSCD
- U1EMC19331 (Autre subvention/numéro de financement: Health Resources and Services Administration)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .